Mark A. Wilson Net Worth

The estimated Net Worth of Mark Andrew Wilson is at least $1.51 Million dollars as of 19 August 2024. Mr Wilson owns over 5,651 units of Nektar Therapeutics stock worth over $281,579 and over the last 4 years he sold NKTR stock worth over $448,482. In addition, he makes $780,492 as Sr. VP and Gen. Counsel & Sec. at Nektar Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Wilson NKTR stock SEC Form 4 insiders trading

Mr has made over 19 trades of the Nektar Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 5,651 units of NKTR stock worth $7,233 on 19 August 2024.

The largest trade he's ever made was selling 8,690 units of Nektar Therapeutics stock on 16 November 2022 worth over $31,023. On average, Mr trades about 3,953 units every 68 days since 2020. As of 19 August 2024 he still owns at least 225,263 units of Nektar Therapeutics stock.

You can see the complete history of Mr Wilson stock trades at the bottom of the page.

Mr. Mark A. Wilson biography

Mark A. Wilson is the Sr. VP, Gen. Counsel & Sec. at Nektar Therapeutics.

What is the salary of Mr Wilson?

As the Sr. VP and Gen. Counsel & Sec. of Nektar Therapeutics, the total compensation of Mr Wilson at Nektar Therapeutics is $780,492. There are 9 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.

How old is Mr Wilson?

Mr Wilson is 49, he's been the Sr. VP and Gen. Counsel & Sec. of Nektar Therapeutics since . There are 12 older and 5 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.

What's Mr Wilson's mailing address?

Mark's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO, CA, 94158.

Insiders trading at Nektar Therapeutics

Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, and John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.

What does Nektar Therapeutics do?

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Complete history of Mr Wilson stock trades at Nektar Therapeutics

Nektar Therapeutics executives and stock owners

Nektar Therapeutics executives and other stock owners filed with the SEC include:

• Jonathan Zalevsky,
  Chief Research and Development Officer
• Howard Robin,
  President, Chief Executive Officer, Director
• Gilbert Labrucherie,
  Chief Financial Officer, Chief Operating Officer, Senior Vice President
• John Northcott,
  Senior Vice President and Chief Commercial Officer
• Howard W. Robin,
  CEO, Pres & Director
• Jillian Thomsen,
  Senior Vice President - Finance, Chief Accounting Officer
• Gilbert M. Labrucherie J.D.,
  Sr. VP, CFO & COO
• Dr. Jonathan Zalevsky,
  Chief R&D Officer
• John P. Northcott,
  Sr. VP & Chief Commercial Officer
• Mark A. Wilson,
  Sr. VP, Gen. Counsel & Sec.
• Myriam Curet,
  Independent Director
• Robert Chess,
  Independent Chairman of the Board
• Roy Whitfield,
  Lead Independent Director
• R. Scott Greer,
  Independent Director
• Karin Eastham,
  Independent Director
• Jeff Ajer,
  Independent Director
• Dr. Brian L. Kotzin,
  Sr. VP of Clinical Devel. & Head of Immunology
• Dr. Mary Tagliaferri L.Ac., M.D.,
  Sr. VP & Exec. Clinical Fellow
• Jennifer Ruddock,
  Sr. VP of Strategy & Corp. Affairs
• Robert Bacci,
  Sr. VP of HR and Facilities
• Jillian B. Thomsen,
  Sr. VP of Fin. & Chief Accounting Officer
• Lutz Lingnau,
  Director
• Dennis L Winger,
  Director
• Ivan P. Gergel,
  SVP Drug Development & CMO
• Maninder Hora,
  SVP Pharma Dev and Mfg
• Christopher A Kuebler,
  Director
• Joseph J Krivulka,
  Director
• Melvin Perelman,
  Director
• Ajit Gill,
  CEO & President
• Track Capital, Lp Deep Trac...,
  
• Randall W Moreadith,
  SVP Drug Development
• Bharat M Chowrira,
  COO & Head of PEGylation BU
• Robert Medve,
  Chief Medical Officer
• Nevan C Elam,
  General Counsel and Secretary
• Timothy Harkness,
  SVP & Chief Financial Officer
• John Stuart Patton,
  Chief Scientific Officer
• Irwin Lerner,
  Director
• Michael A/Ca Brown,
  Director
• Masuoka K. Lorianne,
  SVP & Chief Medical Officer
• Susan Wang,
  Director
• Rinko Ghosh,
  SVP & Chief Business Officer
• David Johnston,
  SVP, Research & Development
• Ajay Bansal,
  CFO, VP Finance & Admin
• Hoyoung Huh,
  Chief Operating Officer
• J Milton Harris,
  President of Nektar AL
• James B Glavin,
  Director
• John Nicholson,
  SVP & Chief Operating Officer
• Stephen K Doberstein,
  SVP & Chief Scientific Officer
• Gil M Labrucherie,
  SVP, COO & CFO
• Diana Brainard,
  Director
• Mark Andrew Wilson,
  Chief Legal Officer